200 results on '"Descourt, Renaud"'
Search Results
2. Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)
3. Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer
4. Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study
5. First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)
6. Uncommon MET Mutational Landscape in a Non-Small Cell Lung Cancer Patient Treated with Crizotinib: Case Report
7. Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study
8. Incidence of venous thromboembolism and association with PD-L1 expression in advanced non-small cell lung cancer patients treated with first-line chemo-immunotherapy
9. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)
10. Case Report: Coronaro-bronchial fistula vascularizing a squamous cell lung cancer
11. Three-Year Overall Survival of Patients With Advanced Non–Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study)
12. Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small–cell lung cancers: An open phase II study using concurrent cisplatin–oral vinorelbine and radiotherapy (GFPC 08-06)
13. Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France
14. Three-Year Overall Survival of Patients With Advanced Non–Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study).
15. Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29)
16. Tinzaparin and VKA use in patients with cancer associated venous thromboembolism: A retrospective cohort study
17. Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy
18. Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study)
19. Progression of Focal to Diffuse Thyroid Uptake Detected by 18F-FDG PET/CT: Malignant Metastatic Disease or Benign Thyroiditis?
20. Real‐life second‐line epirubicin–paclitaxel regimen as treatment of relapsed small‐cell lung cancer: EpiTax study
21. Le point sur la toxicité pulmonaire des G-CSF
22. First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)
23. Real-life experience of rare hepatoid adenocarcinomas of the lung: A large retrospective french cohort.
24. Lorlatinib for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer: Results of the IFCT-1803 LORLATU cohort
25. Infection et thrombose sur chambre implantable : diagnostic et prise en charge thérapeutique
26. Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced Non-small Cell Lung Cancer: The GFPC 05-03 Study
27. Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study
28. Paclitaxel–bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study
29. Real‐life second‐line epirubicin–paclitaxel regimen as treatment of relapsed small‐cell lung cancer: EpiTax study.
30. First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50%
31. Henoch–Schönlein Purpura Associated with Lung Cancer: When Paraneoplastic Manifestations Impede Oncological Management
32. Encephalitis related to immunotherapy for lung cancer: Analysis of a multicenter cohort
33. Efficacy of weekly paclitaxel-bevacizumab combination in advanced nonsquamous non-small cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study.
34. First-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥ 50%) advanced non-small cell lung cancer (aNSCLC) in the real world: A national French bispective multicentric cohort—ESCKEYP trial (GFPC 05-2018).
35. Vascular Acrosyndromes Associated With Prolonged Tumor Response in Advanced Lung Cancer Patients During Treatment With Antimetabolites: A Report of Two Cases
36. Durvalumab‐induced lesions of bronchiolitis and fully reversible bronchiectasis in a patient with non‐small cell lung cancer: A case report
37. Three cases of immune cholangitis related to anti–programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer
38. Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free-survival and overall survival in non-small cell lung cancer: an original cohort study
39. Lorlatinib for advanced ALK and ROS1+ non-small cell lung cancer (NSCLC): Efficacy and treatment sequences in the IFCT-1803 LORLATU expanded access program (EAP) cohort.
40. Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
41. First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study
42. Efficacité et tolérance du brigatinib chez des patients pris en charge pour un cancer bronchopulmonaire non à petite cellules avec translocation ALK en France. Etude BRIGALK
43. A Mismatch Repair–Deficient Hepatoid Adenocarcinoma of the Lung Responding to Anti–PD-L1 Durvalumab Therapy Despite no PD-L1 Expression
44. Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis
45. Brigatinib in pretreated patients with ALK-positive advanced NSCLC.
46. False Positive 18F-FDG Positron Emission Tomography Findings in Schwannoma—A Caution for Reporting Physicians
47. Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial
48. When lung cancer was rare: An historical study of prevalence from 1760.
49. Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review
50. Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: An open phase II study using concurrent cisplatin - oral vinorelbine and radiotherapy (GFPC 08-06).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.